These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 1374729)
1. [Prostatic specific antigen for detection and monitoring of prostatic cancer]. Gofrit O; Pode D; Gez E; Pfau A; Roizman I; Lifshitz Y; Barak V Harefuah; 1992 Mar; 122(6):345-8, 408. PubMed ID: 1374729 [TBL] [Abstract][Full Text] [Related]
2. [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma]. Stamey TA Urologe A; 1990 Mar; 29(2):52-64. PubMed ID: 1691883 [TBL] [Abstract][Full Text] [Related]
3. [Value of determining prostate specific antigen in follow-up of prostatic cancer]. Sadeh AD; Mukamel E; Galili Y; Nussbaum B; Regev D; Servadio C Harefuah; 1993 Aug; 125(3-4):69-74, 128. PubMed ID: 7693556 [TBL] [Abstract][Full Text] [Related]
4. [The clinical use of the prostate-specific antigen in patients with prostatic cancer]. Matveev BP; Sokolov AV; Bukharkin BV; Ledian KM; Tilk AE; Makarova GV Urol Nefrol (Mosk); 1991; (4):8-12. PubMed ID: 1719686 [TBL] [Abstract][Full Text] [Related]
5. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285 [TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker. Mulders TM; Bruning PF; Bonfrer JM Eur J Surg Oncol; 1990 Feb; 16(1):37-41. PubMed ID: 1689677 [TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer. Kabalin JN Geriatrics; 1992 Sep; 47(9):26-32. PubMed ID: 1380941 [TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. Stamey TA; Yang N; Hay AR; McNeal JE; Freiha FS; Redwine E N Engl J Med; 1987 Oct; 317(15):909-16. PubMed ID: 2442609 [TBL] [Abstract][Full Text] [Related]
9. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412 [TBL] [Abstract][Full Text] [Related]
10. [PSA in the staging and monitoring of cancer of the prostate]. Gil Sanz MJ; Sanz Velez JI; Liedana Torres JM; Roncales Badal AL; Allepuz Losa C; Rioja Sanz LA Actas Urol Esp; 1991; 15(6):527-31. PubMed ID: 1724347 [TBL] [Abstract][Full Text] [Related]
11. [Prostate-specific antigen (PSA): diagnostic and prognostic implications in the evaluation of carcinoma of the prostate]. Lo Cigno M; Montanari F; Bercovich E; Soli M; Emili E; Dal Pozzo C; Platè L; Bianchi D Arch Ital Urol Nefrol Androl; 1989 Mar; 61(1):29-36. PubMed ID: 2469127 [TBL] [Abstract][Full Text] [Related]
12. [The value of prostate-specific antigen in therapy follow-up of prostatic carcinoma]. Wirth MP; Pilarsky C Urologe A; 1995 Jul; 34(4):297-302. PubMed ID: 7545844 [TBL] [Abstract][Full Text] [Related]
13. [Determination of prostatic specific antigen and prostatic acid phosphatase as tumor markers of cancer of the prostate]. Morote Robles J; de Torres Mateos JA Arch Esp Urol; 1989; 42 Suppl 2():124-30. PubMed ID: 2484148 [TBL] [Abstract][Full Text] [Related]
14. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Miller N; Smolkin ME; Bissonette E; Theodorescu D Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361 [TBL] [Abstract][Full Text] [Related]
15. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Sheridan T; Herawi M; Epstein JI; Illei PB Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190 [TBL] [Abstract][Full Text] [Related]
16. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993. Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430 [TBL] [Abstract][Full Text] [Related]